secwatch.observer — SEC 8-K summary
======================================

Issuer:     IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
CIK:        0001425205
Form:       8-K
Filed at:   2026-06-10T21:01:03+00:00
Accession:  0001104659-26-072408
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iovance's Amtagvi granted TGA approval in Australia for advanced melanoma
-------------------------------------------------------------------------

- Therapeutic Goods Administration of Australia approved Amtagvi for previously treated advanced melanoma.
- Indicated for patients who received anti-PD-1 therapy and, if BRAF V600+, a BRAF/MEK inhibitor.
- Third marketing authorization for Amtagvi; Iovance is authorizing its first Australian treatment center.
- Australia has the world's highest melanoma rate, with ~17,000 new cases annually.
- Approval based on Phase 2 C-144-01 trial results showing objective response rate and duration of response.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1425205/000110465926072408/0001104659-26-072408-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1425205/000110465926072408/tm2613648d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-072408

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer